Utility of post-admission SARS-CoV-2 serial testing in hospitalized patients with cancer
In summary, post-admission serial testing in a high-risk setting is a low-yield strategy with several unfavorable effects and should no longer be routinely applied.
Authors
- N. Esther Babady (ORCID: https://orcid.org/0000-0003-4399-1249)
- Judy Yan (ORCID: https://orcid.org/0009-0005-2174-218X)
- Anoshé Aslam (ORCID: https://orcid.org/0000-0003-0248-3192)
- Tania N Bubb (ORCID: https://orcid.org/0009-0008-4636-1422)
- Shauna Usiak (ORCID: https://orcid.org/0000-0002-9407-7513)
- Tiffany Romero
- Mini Kamboj (ORCID: https://orcid.org/0000-0002-3122-6374)
- Marissa Bokhari (ORCID: https://orcid.org/0000-0003-2785-8456)
- Rich Kodama (ORCID: https://orcid.org/0000-0003-3933-5548)
- Jerin Madhavappallil
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
Publication Details
- Journal
- Infection Control and Hospital Epidemiology
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1017/ice.2024.174
- Primary Topic
- SARS-CoV-2 detection and testing
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Memorial Sloan-Kettering Cancer Center